Circassia Pharmaceuticals (CSSPF) Income Statement
Circassia Pharmaceuticals Income Statement
Last quarter (Q2 2026), Circassia Pharmaceuticals's total revenue was $24.00M, an increase of 14.29% from the same quarter last year. In Q2, Circassia Pharmaceuticals's net income was $5.90M. See Circassia Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 48.70M | $ 41.80M | $ 36.80M | $ 31.30M | $ 27.90M | |
| $ 29.60M | $ 30.20M | $ 26.50M | $ 22.20M | $ 19.00M | |
| $ 18.90M | $ 22.50M | $ 21.90M | $ 20.40M | $ 23.30M | |
| Depreciation and Amortization | $ 4.10M | $ 4.20M | $ 4.40M | $ 4.60M | $ 4.90M |
| $ 14.80M | $ 12.20M | $ 8.60M | $ 15.20M | $ 3.10M | |
| $ 10.70M | $ 7.70M | $ 4.60M | $ 1.80M | $ -4.30M | |
| $ 500.00K | $ 100.00K | $ -500.00K | $ 8.70M | $ 2.20M | |
| $ 11.20M | $ 7.80M | $ 4.10M | $ 10.50M | $ -2.10M | |
| $ 7.00M | $ 3.70M | $ 10.70M | $ 16.10M | $ 3.60M | |
| Per Share Metrics | |||||
| Basic EPS | $ 0.02 | $ 0.01 | $ 0.03 | $ 0.04 | $ 0.01 |
| Diluted EPS | $ 0.02 | $ 0.01 | $ 0.02 | $ 0.04 | $ 0.01 |
| Weighted Average Shares Outstanding | 414.17M | 418.21M | 420.20M | 419.20M | 412.61M |
| Weighted Average Shares Outstanding (Diluted) | 426.22M | 448.21M | 449.28M | 443.00M | 435.83M |
Currency in GBP
